Regulation of cytokine production during phagocytosis of apoptotic cells

Cell Research

Volumn 16, Issue 2, 2006, Pages 154-161

  Chung, Elaine Y ^a   Sun, Jung Kim ^b   Xiao, Jing Ma ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Apoptotic cells; Autoimmunity; Cytokines; Phagocytosis

Indexed keywords

GC BINDING PROTEIN, MOUSE; GC-BINDING PROTEIN, MOUSE; INTERLEUKIN 10; INTERLEUKIN 12; LIGAND; REPRESSOR PROTEIN;

ANIMAL; APOPTOSIS; AUTOIMMUNE DISEASE; CONFERENCE PAPER; GENETICS; HOMEOSTASIS; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; MACROPHAGE ACTIVATION; METABOLISM; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; AUTOIMMUNE DISEASES; HOMEOSTASIS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-12; LIGANDS; MACROPHAGE ACTIVATION; MACROPHAGES; PHAGOCYTOSIS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION;

EID: 32644454550     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/sj.cr.7310021     Document Type: Conference Paper

References (103)

1. Wyllie AH, Kerr JF Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68:251-306.
2. Savill J, Fadok V, Henson P Haslett C. Phagocyte recognition of cells undergoing apoptosis. Immunol Today 1993; 14:131-6.
3. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188:1359-68.
4. Fadok VA, Voelker DR, Campbell PA, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148:2207-16.
5. Verhoven B, Schlegel RA Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med 1995; 182:1597-601.
6. Frasch SC, Henson PM, Kailey JM, et al. Regulation of phospholipid scramblase activity during apoptosis and cell activation by protein kinase Cdelta. J Biol Chem 2000; 275:23065-73.
7. Hoffmann PR, deCathelineau AM, Ogden CA, et al. Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J Cell Biol 2001; 155:649-59.
8. Savill J Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000; 407:784-8.
9. Fadok VA, Bratton DL, Rose DM, et al. A receptor for phosphatidylserine- specific clearance of apoptotic cells. Nature 2000; 405:85-90.
10. Henson PM, Bratton DL Fadok VA. Apoptotic cell removal. Curr Biol 2001; 11:R795-805.
11. Williamson P Schlegel RA. Hide and seek: the secret identity of the phosphatidylserine receptor. J Biol 2004; 3:14.
12. Somersan S Bhardwaj N. Tethering and tickling: a new role for the phosphatidylserine receptor. J Cell Biol 2001; 155:501-4.
13. Grigg JM, Savill JS, Sarraf C, et al. Neutrophil apoptosis and clearance from neonatal lungs. Lancet 1991; 338:720-2.
14. Haslett C, Savill JS, Whyte MK, et al. Granulocyte apoptosis and the control of inflammation. Philos Trans R Soc Lond B Biol Sci 1994; 345:327-33.
15. Cox G, Crossley J, Xing Z. Macrophage engulfment of apoptotic neutrophils contributes to the resolution of acute pulmonary inflammation in vivo. Am J Respir Cell Mol Biol 1995; 12:232-7.
16. Voll RE, Roth EA, Girkontaite I, et al. Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis Rheum 1997; 40:2162-71.
17. Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit promflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998; 101:890-8.
18. Sun EW Shi YF. Apoptosis: the quiet death silences the immune system. Pharmacol Ther 2001; 92:135-45.
19. Herrmann M, Voll RE, Zoller OM et al. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41:1241-50.
20. Baumann I, Kolowos W, Voll RE, et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46:191-201.
21. Perniok A, Wedekind F, Herrmann M, et al. High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus 1998; 7:113-8.
22. Raptis L Menard HA. Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus. J Clin Invest 1980; 66:1391-9.
23. McCoubrey-Hoyer A, Okarma TB Holman HR. Partial purification and characterization of plasma DNA and its relation to disease activity in systemic lupus erythematosus. Am J Med 1984; 77:23-34.
24. Steinman CR. Circulating DNA in systemic lupus erythematosus. Isolation and characterization. J Clin Invest 1984; 73:832-41.
25. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13:251-76.
26. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13:715-25.
27. Trembleau S, Germann T, Gately MK Adorini L. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 1995; 16:383-6.
28. Caspi RR. IL-12 in autoimmunity. Clin Immunol Immunopathol 1998; 88:4-13.
29. Trembleau S, Penna G, Bosi E, et al. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 1995; 181:817-21.
30. Leonard JP, Waldburger KE, Schaub RG, et al. Regulation of the inflammatory response in animal models of multiple sclerosis by interleukin-12. Crit Rev Immunol 1997; 17:545-53.
31. Rothe H, O'Hara RM, Jr., Martin S Kolb H. Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)- 12 antagonist IL-12(p40)2. Diabetologia 1997; 40:641-6.
32. Trembleau S, Penna G, Gregori S, et al. Deviation of pancreas- infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur J Immunol 1997; 27:2330-9.
33. Leonard JP, Waldburger KE Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995; 181:381-6.
34. Constantinescu CS, Wysocka M, Hilliard B, et al. Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J Immunol 1998; 161:5097-104.
35. Yokoi H, Kato K, Kezuka T, et al. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12. Eur J Immunol 1997; 27:641-6.
36. Tarrant TK, Silver PB, Chan CC, et al. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis. J Immunol 1998; 161:122-7.
37. Mclntyre KW, Shuster DJ, Gillooly KM, et al. Reduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient mice. Eur J Immunol 1996; 26:2933-8.
38. Liu J Beller D. Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-kappa B expression and binding to the IL-12 p40 promoter. J Immunol 2002; 169:581-6.
39. Simpson PB, Mistry MS, Maki RA, et al. Cuttine edge: diabetes-associated quantitative trait locus, Idd4, is responsible for the IL-12p40 overexpression defect in nonobese diabetic (NOD) mice. J Immunol 2003; 171:3333-7.
40. Segal R, Dayan M, Zinger H, et al. The effect of IL-12 on clinical and laboratory aspects of experimental SLE in young and aging mice. Exp Gerontol 2003; 38:661-8.
41. Wong CK, Ho CY, Li EK Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9:589-93.
42. Robak E, Robak T, Wozniacka A, et al. Proinflammatory interferon-gamma - inducing monokines (interleukin-12, interleukin-18, interleukin-15) - serum profile in patients with systemic lupus erythematosus. Eur Cytokine Netw 2002; 13:364-8.
43. Lauwerys BR, Van Snick J Houssiau FA. Serum IL-12 in systemic lupus erythematosus: absence of p70 heterodimers but presence of p40 monomers correlating with disease activity. Lupus 2002; 11:384-7.
44. Spadaro A, Scrivo R, Rinaldi T, et al. The role of interleukin-12 in immune-mediated rheumatic diseases. Reumatismo 2002; 54:113-21.
45. Li Z, Li Y, Huang L, et al. Expression of interleukin-12 and its signaling molecules in peripheral blood mononuclear cells in systemic lupus erythematosus patients. Chin Med J (Engl) 2002; 115:846-50.
46. Filatenkov AA, Jacovetty EL, Fischer UB, et al. CD4 T Cell-Dependent Conditioning of Dendritic Cells to Produce IL-12 Results in CD8-Mediated Graft Rejection and Avoidance of Tolerance. J Immunol 2005; 174:6909-17.
47. Eaton AD, Xu D, Garside P. Administration of exogenous interleukin-18 and interleukin-12 prevents the induction of oral tolerance. Immunology 2003; 108:196-203.
48. Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16:779-90.
49. Chen Q, Ghilardi N, Wang H, et al. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 2000; 407:916-20.
50. Yoshida H, Hamano S, Senaldi G, et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 2001; 15:569-78.
51. Salcedo R, Stauffer JK, Lincoln E, et al. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol 2004; 173:7170-82.
52. Chiyo M, Shimozato O, Yu L, et al. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer 2005; 115:437-42.
53. Li J, Gran B, Zhang GX, et al. IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis. J Neurol Sci 2005; 232:3-9.
54. Goldberg R, Zohar Y, Wildbaum G, et al. Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27. J Immunol 2004; 173:6465-71.
55. Kim S, Elkon KB, Ma X. Transcriptional Suppression of Interleukin-12 Gene Expression following Phagocytosis of Apoptotic Cells. Immunity 2004; 21:643-53.
56. Kim S, Chung EY, Ma X. Immunological Consequences of Macrophage-mediated Clearance of Apoptotic Cells. Cell Cycle 2005; 4:231-4.
57. Burke PS, Don J, Wolgemuth DJ. Zfp-51, a murine zinc finger encoding gene mapping to the t-complex region of chromosome 17, encodes 19 contiguous zinc fingers and is ubiquitously expressed. Mamm Genome 1994; 5:387-9.
58. Vanden Heuvel JP, Holden P, Tugwood J, et al. Identification of a novel peroxisome proliferator responsive cDNA isolated from rat hepatocytes as the zinc-finger protein ZFP-37. Toxicol Appl Pharmacol 1998; 152:107-18.
59. Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol 2004; 20:455-80.
60. Natarajan C, Bright JJ. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 2002; 3:59-70.
61. Kim S, Chung EY, Ma X. Immunological consequences of macrophage-mediated clearance of apoptotic cells. Cell Cycle 2005; 4:231-4.
62. Moore KW, Vieira P, Fiorentino DF, et al. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein- Barr virus gene BCRFI. Science 1990; 248:1230-4.
63. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-24.
64. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444-51.
65. Ding L, Shevach EM. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 1992; 148:3133-9.
66. Hsu DH, Moore KW, Spits H. Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity. Int Immunol 1992; 4:563-9.
67. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991; 174:1549-55.
68. de Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20.
69. Fiorentino DF, Zlotnik A, Mosmann TR, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147:3815-22.
70. Ding L, Linsley PS, Huang LY, et al. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151:1224-34.
71. Gazzinelli RT, Oswald IP, James SL Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN- gamma-activated macrophages. J Immunol 1992; 148:1792-6.
72. Oswald IP, Gazzinelli RT, Sher A James SL. IL-10 synergizes with IL-4 and transforming growth factor-beta to inhibit macrophage cytotoxic activity. J Immunol 1992; 148:3578-82.
73. Ralph P, Nakoinz I, Sampson-Johannes A, et al. IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992; 148:808-14.
74. Murphy EE, Terres G, Macatonia SE, et al. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 1994; 180:223-31.
75. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263-74.
76. Berg DJ, Leach MW, Kuhn R, et al. Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses. J Exp Med 1995; 182:99-108.
77. Berg DJ, Kuhn R, Rajewsky K, et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 1995; 96:2339-47.
78. Bettelli E, Das MP, Howard ED, et al. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol 1998; 161:3299-306.
79. Fuss IJ, Boirivant M, Lacy B Strober W. The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J Immunol 2002; 168:900-8.
80. Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002; 30:S58-S63.
81. Conti P, Kempuraj D, Kandere K, et al. IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol Lett 2003; 86:123-9.
82. Chen WF Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 1991; 147:528-34.
83. Groux H, Cottrez F, Rouleau M, et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol 1999; 162:1723-9.
84. Takayama T, Tahara H, Thomson AW. Differential effects of myeloid dendritic cells retrovirally transduced to express mammalian or viral interleukin-10 on cytotoxic T lymphocyte and natural killer cell functions and resistance to tumor growth. Transplantation 2001; 71:1334-40.
85. Carson WE, Lindemann MJ, Baiocchi R, et al. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995; 85:3577-85.
86. Thompson LM, Rubin RT, McCracken JT. Neuroendocrine aspects of primary endogenous depression: XII. Receiver operating characteristic and kappa analyses of serum and urine cortisol measures in patients and matched controls. Psychoneuroendocrinology 1992; 17:507-15.
87. MacNeil IA, Suda T, Moore KW, et al. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 1990; 145:4167-73.
88. Groux H, Cottrez F. The complex role of interleukin-10 in autoimmunity. J Autoimmun 2003; 20:281-5.
89. Grove M, Plumb M. C/EBP, NF-kappa B, and c-Ets family members and transcriptional regulation of the cell-specific and inducible macrophage inflammatory protein 1 alpha immediate-early gene. Mol Cell Biol 1993; 13:5276-89.
90. Matsusaka T, Fujikawa K, Nishio Y, et al. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A 1993; 90:10193-7.
91. Stein B, Baldwin AS Jr. Distinct mechanisms forregulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NF-kappa B. Mol Cell Biol 1993; 13:7191-8.
92. Murphy TL, Cleveland MG, Kulesza P, et al. Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol Cell Biol 1995; 15:5258-67.
93. Ma X, Chow JM, Gri G, et al. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med 1996; 183:147-57.
94. Ma X, Neurath M, Gri G, Trinchieri G. Identification and characterization of a novel Ets-2-related nuclear complex implicated in the activation of the human interleukin-12 p40 gene promoter. J Biol Chem 1997; 272:10389-95.
95. Plevy SE, Gemberling JH, Hsu S, et al. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Re1 proteins. Mol Cell Biol 1997; 17:4572-88.
96. Grazia Cappiello M, Sutterwala FS, Trinchieri G, et al. Suppression of I1-12 transcription in macrophages following Fc gamma receptor ligation. J Immunol 2001; 166:4498-506.
97. Yssel H, De Waal Malefyt R, Roncarolo MG, et al. IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J Immunol 1992; 149:2378-84.
98. Brightbill HD, Plevy SE, Modlin RL, Smale ST. A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. J Immunol 2000; 164:1940-51.
99. Tone M, Powell MJ, Tone Y, et al. IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol 2000; 165:286-91.
100. Powell MJ, Thompson SA, Tone Y, et al. Posttranscriptional regulation of IL-10 gene expression through sequences in the 3'-untranslated region. J Immunol 2000; 165:292-6.
101. Brewer G, Saccani S, Sarkar S, et al. Increased interleukin-10 mRNA stability in melanoma cells is associated with decreased levels of A + U-rich element binding factor AUF1. J Interferon Cytokine Res 2003; 23:553-64.
102. Benkhart EM, Siedlar M, Wedel A, et al. Role of Stat3 in lipopolysaccharide-induced IL-10 gene expression. J Immunol 2000; 165:1612-7.
103. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.